Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615 · View on ClinicalTrials.gov ↗
Study Summary
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Inebilizumab
Study Locations (20)
California
- Children's Hospital of Orange County — Orange
- UC Irvine — Orange
- UC Davis — Sacramento
Arizona
- St. Joseph Hospital and Medical Center Barrow Neurological Institute — Phoenix
- Mayo Clinic in Arizona — Scottsdale
Colorado
- Children's Hospital Colorado Main Campus — Aurora
- University of Colorado — Aurora
Florida
- Mayo Clinic Jacksonville — Jacksonville
- University of Miami — Miami
Illinois
- Ann and Robert H. Lurie Childrens Hospital of Chicago — Chicago
- Northwestern University Feinberg School of Medicine — Chicago
Alabama
- University of Alabama at Birmingham — Birmingham
Connecticut
- Yale University — New Haven
Georgia
- Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04372615
The ClinicalTrials.gov registry entry for NCT04372615 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 686 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Encephalitis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04372615 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Arizona, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04372615 about?
NCT04372615 is a clinical study titled "The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis". Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
What is the current status of trial NCT04372615?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2022-03-30. Estimated completion is 2028-09-30.
What conditions does trial NCT04372615 study?
This clinical trial studies the following conditions: Encephalitis, Autoimmune Encephalitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04372615?
The interventions under investigation include: Placebo (DRUG), Inebilizumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04372615?
This trial is sponsored by University of Utah, which has 686 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04372615 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.